Parents Demand Wider Meningitis B Vaccine Access After Daughter Dies

Tragic Loss Sparks Urgent Calls for Change

Helen and Lee Draper's 18-year-old daughter Meg died from MenB while studying at the University of Bournemouth in October 2025. Meg had been vaccinated against meningitis strains A, C, W and Y when she was 14 through the NHS vaccination schedule but not MenB, as this is only offered to young children born after 2015. The devastating loss occurred just months before a deadly outbreak would claim two more young lives and expose critical gaps in the UK's vaccination strategy.

Meg's death came months before an "unprecedented" outbreak of MenB in Kent, which resulted in the deaths of two young people. The UK government subsequently asked the Joint Committee on Vaccination and Immunisation (JCVI) to "reexamine eligibility for meningitis vaccines" for teenagers and young adults. In March 2026, an outbreak of meningococcal meningitis and sepsis occurred at the University of Kent in the southeastern corner of England. Twenty cases were confirmed and nine were suspected. All confirmed cases were hospitalized and virtually all were caused by the serogroup B strain of meningococcus (i.e., MenB) for which a vaccine is available. Two students died during the outbreak: one was an unnamed student at the University, the other was Juliette Kenny, a 12th grader at a nearby high school.

The Vaccination Gap That Costs Lives

The MenB vaccine is only available on the NHS in England and Wales for young children born after May 2015, as they are seen as the most at risk. For older children or adults, a MenB vaccine or booster costs about £220 privately. This creates a dangerous protection gap for exactly the age group most vulnerable to campus outbreaks.

While MenB is described as "rare" in those over four, there is a second, less common peak in teenagers. The JCVI, a scientific advisory committee that advises both the UK and Welsh government on vaccinations, concluded in 2014 that vaccinating teenagers and young adults against MenB was "not cost effective". Mrs Simpson said her son had the MenACWY vaccine but it is "confusing messaging" for parents who think they have done all they can to protect their child by taking up the vaccines offered by the NHS. She said: "It's just very confusing for parents when you find out that there's a vaccine. If we had known that there was a menB vaccine, Ross would have had that vaccine in a heartbeat, without question."

Swift Action Could Prevent Future Tragedies

Helen and Lee said they feared "another outbreak like Kent could happen again" if the MenB vaccine was not made available to 15-24-year-olds on the NHS. Their fears are well-founded given the disease's rapid progression and devastating consequences. People should understand that meningococcal group B disease is rare but extremely serious, and it can progress very quickly. Early symptoms may seem mild, but the illness can become life-threatening within hours.

More than 8,000 doses of the vaccine were administered to anxious students. Every year in the United States between 300 and 500 people are infected with meningococcus, half of those cases are caused by MenB. We shouldn't wait until a disease is at our doorstep to vaccinate our teenagers before they enter college. The Kent outbreak demonstrates how quickly authorities can mobilize vaccination campaigns when lives are at stake, raising questions about why such protection isn't routinely available.

A Path Forward Through Awareness and Access

The tragedy has prompted government action, with Health Secretary Wes Streeting requesting fresh guidance from vaccination advisors. Yet for families like the Drapers, policy changes come too late. Their daughter's death highlights a cruel irony: effective vaccines exist, but bureaucratic determinations about cost-effectiveness leave vulnerable young adults unprotected.

Universities are beginning to respond with increased awareness campaigns and vaccination clinics, but the patchwork approach leaves students' health dependent on geography and institutional resources. For families with teenagers and young adults, this is also a good time to review meningococcal vaccination, including asking specifically about MenB. Everyone should be aware of their vaccination history, including whether they are vaccinated against MenB. The Drapers' advocacy ensures their daughter's death becomes a catalyst for protecting other families from experiencing the same devastating loss.